---
title: "Safety Reporting & Signal Detection — Pharmacovigilance | QbD Group"
description: "Safety reporting is a critical component of pharmacovigilance and post-marketing surveillance. At QbD Group, we analyze and deliver safety reports that ens"
url: https://qbdgroup.com/en/services/pharmacovigilance/aggregate-safety-reporting
type: "Page"
language: en
publisher: "QbD Group"
citation: "QbD Group, \"Safety Reporting & Signal Detection — Pharmacovigilance | QbD Group\", https://qbdgroup.com/en/services/pharmacovigilance/aggregate-safety-reporting"
---

# Safety Reporting & Signal Detection

Comprehensive safety reporting tailored to your needs

Safety reporting is a critical component of pharmacovigilance and post-marketing surveillance. At QbD Group, we analyze and deliver safety reports that ensure compliance with global regulatory requirements.

## What is safety reporting?

Safety reporting involves the **periodic collection, analysis, and submission of safety data from multiple sources**. These reports provide a holistic view of a product's safety profile and are essential for ongoing regulatory compliance and risk mitigation.

Key types of safety reports:
- **IND Annual Reports**: Documenting safety information from clinical trials for investigational drugs.
- **Clinical Study Reports (CSRs)**: Comprehensive summaries of clinical trial data.
- **New Drug Applications (NDAs)**: Safety data submitted for regulatory approval of new drugs.
- **Periodic Safety Update Reports (PSURs) / Periodic Benefit-Risk Evaluation Reports (PBRERs)**: Post-marketing safety evaluations.
- **Development Safety Update Reports (DSURs)**: Ongoing assessments during clinical development.
- **Signal detection**: Comprehensive signal management — from data collection to regulatory reporting — delivering actionable insights for proactive risk mitigation.

## Why is safety reporting essential?

### Regulatory adherence

Meet global reporting requirements and avoid penalties or delays.

### Risk management

Identify and address emerging safety signals early.

### Product confidence

Provide stakeholders with clear evidence of a product's safety and efficacy.

### Streamlined processes

Efficiently manage and submit comprehensive safety data.

### Timely risk identification

Early detection of potential safety issues prevents escalation and reduces harm.

## How can we help?

QbD Group's safety reporting services leverage advanced methodologies, including the PSO/ACO classification approach, to deliver precise and actionable insights:

### Report compilation and delivery

IND Annual Reports, CSRs, NDAs, PSURs/PBRERs, and DSURs tailored to meet your regulatory needs.

### Advanced methodologies

Utilizing PSO/ACO for classification and rule discovery to optimize post-marketing surveillance.

### Regulatory expertise

Ensure alignment with EMA, FDA, and other global authorities.

### Comprehensive solutions

From data analysis to report submission, we manage the entire process.

### Custom workflows

Tailored reporting strategies that align with your operational goals.

### Expert risk management

Evaluating and classifying signals to determine their clinical significance.

Why QbD Group

## Your trusted partner

Choosing QbD Group for safety reporting ensures:

Expert knowledge

decades of experience in pharmacovigilance and regulatory compliance.

Innovative approaches

advanced methodologies like PSO/ACO for superior safety data analysis.

Seamless service

end-to-end support from data collection to regulatory submission.

Proven track record

successful delivery of safety reports for a wide range of products and markets.

## Let's talk Pharmacovigilance

From QPPV services to signal management, our safety experts are ready to support your pharmacovigilance needs.

Contact us

---

Source: https://qbdgroup.com/en/services/pharmacovigilance/aggregate-safety-reporting — © QbD Group. Quote freely with attribution and a link back.